Moderna (MRNA) traded lower on April 23, 2026, extending a choppy tape as investors weighed fresh oncology messaging from this week’s AACR meeting against a near-term catalyst calendar that now shifts to earnings. The move looks driven more by positioning and sentiment than a single new negative headline, with traders fading recent conference-driven interest and de-risking into the May 1 results.

In recent days, Moderna highlighted data for mRNA-4359 at the 2026 AACR Annual Meeting in San Diego (April 17–22, 2026). While the company framed the presentation as progress for its oncology platform, early-stage cancer readouts typically leave wide uncertainty around durability, registrational pathways, and timelines—often leading to “sell-the-news” trading when there isn’t an immediate catalyst to re-rate the shares.

MRNA’s tape remains sensitive to updates around respiratory franchise expansion and cash runway. Earlier this year the FDA issued a refusal-to-file letter for Moderna’s standalone seasonal flu vaccine (mRNA-1010), a setback that raised questions about U.S. timing even as the company pursued engagement with regulators. Separately, Moderna agreed to settle a long-running COVID-19 vaccine patent dispute with an upfront $950 million payment and indicated it expected to record a $950 million charge in Q1 2026, keeping near-term financial optics in focus even after legal uncertainty eased.

The next major catalyst is Moderna’s first-quarter 2026 earnings report and conference call scheduled for May 1, 2026. Investors will be listening for updated 2026 revenue expectations, expense discipline and cash trajectory, and any clearer regulatory timelines for the standalone flu vaccine and broader respiratory pipeline—plus a tighter view of which oncology programs could become value-driving, late-stage assets.